← GLOBUS MEDICAL INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $564.0m | $636.0m | $713.0m | $785.4m | $789.0m | $958.1m | $1.0b | $1.6b | $2.5b | $2.9b | |
| Cost of Revenue | $134.7m | $150.5m | $159.4m | $180.0m | $217.5m | $239.2m | $263.7m | $548.2m | $1.0b | $957.8m | |
| Gross Profit (derived) | $429.3m | $485.5m | $553.6m | $605.4m | $571.6m | $718.9m | $759.1m | $1.0b | $1.5b | $2.0b | |
| Operating Expenses | $275.1m | $323.7m | $384.2m | $433.4m | $460.1m | $546.9m | $531.2m | $887.2m | — | — | |
| Operating Income (Loss) | $154.1m | $161.8m | $169.3m | $172.0m | $111.4m | $172.0m | $228.0m | $133.1m | $166.0m | $479.8m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $3.5m | $7.9m | $9.6m | $13.8m | $16.8m | $18.5m | $17.7m | $51.0m | $119.4m | $118.2m | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($482k) | $909k | $360k | $75k | ($279k) | ($1.4m) | ($1.0m) | $14.3m | ($43.3m) | ($3.0m) | |
| Goodwill, Impairment Loss | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $154.4m | $155.1m | $180.7m | $179.2m | $154.4m | $184.8m | $247.3m | $181.8m | $149.5m | $586.5m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $180.4m | $243.0m | $165.4m | $120.7m | $605.1m | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | — | — | — | — | — | — | — | $14.1m | ($43.3m) | ($3.0m) | |
| Net Income (Loss) Attributable to Parent | $104.3m | $107.3m | $156.5m | $155.2m | $102.3m | $149.2m | $190.2m | $122.9m | $103.0m | $537.9m | |
| Net Income (Loss) Available to Common Stockholders, Basic | $104.3m | $107.3m | $156.5m | $155.2m | $102.3m | $149.2m | $190.2m | $122.9m | $103.0m | $537.9m | |
| Earnings Per Share, Basic | $1.09 | $1.12 | $1.60 | $1.57 | $1.04 | $1.48 | $1.89 | $1.09 | $0.76 | $3.98 | |
| Earnings Per Share, Diluted | $1.08 | $1.10 | $1.54 | $1.52 | $1.01 | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 | |
| Weighted Average Number of Shares Outstanding, Basic | 95.6m | 96.2m | 97.9m | 99.2m | 98.6m | 100.7m | 100.5m | 113.1m | 135.7m | 135.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | 96.4m | 97.9m | 101.3m | 102.0m | 101.0m | 103.6m | 102.6m | 114.6m | 137.9m | 137.1m | |
| Research and Development Expense | $44.5m | $43.7m | $55.5m | $60.1m | $84.5m | $97.3m | $73.0m | $124.0m | $163.8m | $147.2m | |
| Selling, General and Administrative Expense | $222.2m | $267.8m | $311.6m | $354.8m | $354.8m | $408.1m | $432.1m | $643.4m | $981.0m | $1.2b | |
| Other Nonoperating Income (Expense) | $3.1m | $8.1m | $19.3m | $18.0m | $14.5m | $8.5m | $15.1m | $32.3m | $2.2m | $3.4m | |
| Business Combination, Acquisition Related Costs | $1.8m | $1.6m | $1.7m | $2.6m | $4.0m | $17.0m | $6.0m | $68.3m | $29.6m | $42.3m | |
| Current Income Tax Expense (Benefit) | $57.1m | $54.4m | $31.2m | $30.4m | $27.6m | $48.9m | $75.2m | $100.8m | $151.8m | — | |
| Operating Lease, Expense | — | — | — | $3.2m | $3.6m | $3.4m | — | — | — | — | |
| Restructuring Costs | — | — | — | — | — | — | — | $0 | $23.8m | $15.0m | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | $11.7m | $14.9m | $22.2m | $26.4m | $27.3m | $31.3m | $33.5m | $52.8m | $54.3m | $76.5m | |
| Income Tax Expense (Benefit) | $52.9m | $62.6m | $32.1m | $34.7m | $23.6m | $31.2m | $52.9m | $42.5m | $17.7m | $67.2m | |
| Interest Income (Expense), Net | $3.1m | $6.6m | $13.3m | $17.4m | $14.0m | $9.3m | $14.2m | $20.1m | ($4.2m) | $7.1m | |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | — | — | — | $7.1m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.